Welcome to our dedicated page for Myriad Genetics SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Myriad Genetics, Inc. (NASDAQ: MYGN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a molecular diagnostic testing and precision medicine company, Myriad Genetics uses these filings to report financial results, material agreements, leadership changes, and other significant events.
Investors can review Form 8-K filings that announce quarterly financial results, furnish earnings press releases, and describe items such as new credit agreements or changes in executive officers. For example, recent 8-K filings have covered results for quarters ended in 2025, entry into a term loan credit facility, and the appointment or departure of senior finance executives. An 8-K/A amendment has also been used to correct a clerical error in previously furnished financial information.
In addition to current reports, Myriad Genetics files annual reports on Form 10-K and quarterly reports on Form 10-Q, which include audited or reviewed financial statements, risk factor discussions, and segment information for areas such as hereditary cancer testing, tumor profiling, prenatal testing, and pharmacogenomics. Proxy statements and other governance-related documents provide further detail on board structure and executive compensation.
On Stock Titan, these filings are updated as they become available from the SEC’s EDGAR system. AI-powered tools summarize key points, highlight important sections, and help explain complex topics such as non-GAAP financial measures, credit facility covenants, and the implications of executive transitions. Users can also focus on insider and executive-related disclosures within Forms 3, 4, and 5 when those are filed, to better understand equity awards and ownership changes.
This page is intended as a convenient starting point for reviewing Myriad Genetics’ regulatory history and understanding how the company reports its financial condition, strategic agreements, and corporate governance matters over time.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported a routine tax-related share withholding. On March 22, 2026, 2,019 shares of Myriad Genetics common stock were withheld by the company at $4.58 per share to cover tax obligations from vesting restricted stock units.
These shares were not sold in the open market but delivered back to the issuer to satisfy taxes. After this tax-withholding disposition, Muzzey directly holds 327,256 shares of Myriad Genetics common stock, indicating the transaction affects only a small portion of his overall equity position.
Myriad Genetics Chief Operating Officer Mark Verratti reported a routine tax-related share withholding. On March 22, 2026, 2,055 shares of Common Stock were disposed of at $4.58 per share to satisfy tax obligations tied to vesting restricted stock units. The number of shares withheld was based on the March 20, 2026 closing price. After this withholding, Verratti directly owns 630,715 shares of Myriad Genetics Common Stock.
MYRIAD GENETICS INC Chief Financial Officer Benjamin Richard Wheeler had 549 shares of Common Stock withheld by the company to cover tax obligations tied to restricted stock unit vesting. The withheld shares were valued at $4.58 per share, based on the closing price on March 20, 2026.
These shares were not sold in the open market but retained by the issuer to satisfy tax withholding requirements. After this tax-withholding disposition, Wheeler directly holds 298,509 shares of Myriad Genetics common stock.
MYRIAD GENETICS INC Chief Technology Officer Kevin Richard Haas reported share dispositions that were entirely for tax withholding. Over March 13–15, 2026, a total of 22,310 shares of Common Stock were withheld by the company to satisfy tax obligations from vesting restricted and performance-based stock units.
These F-code transactions are not open-market sales and do not reflect discretionary selling activity. After these tax-withholding events, Haas continues to hold 180,022 shares of Common Stock directly.
MYRIAD GENETICS INC Chief People Officer Shereen Solaiman received a large equity award and had shares withheld for taxes. On March 12, 2026, she was granted 173196 time-based restricted stock units under the 2017 equity incentive plan, vesting in three equal annual installments starting on the first anniversary of the grant.
On March 13 and 14, 2026, the company withheld 8899 and 5784 shares of common stock, respectively, to cover tax obligations tied to vesting of previously granted restricted stock units, based on a share price of $4.6600. After these tax-withholding dispositions, she directly holds 267801 shares of common stock.
Myriad Genetics Chief Scientific Officer Dale Muzzey reported equity compensation activity and related tax withholding transactions in company stock. On March 12, 2026, he received 173,196 time-based restricted stock units under the 2017 equity incentive plan, each representing one share of common stock vesting in three equal annual installments beginning on the first anniversary of the grant.
On March 13–15, 2026, a total of 37,799 shares of common stock were withheld by the company at $4.66 per share to satisfy tax obligations on the vesting of previously granted time-based and performance-based restricted stock units. These F-code transactions are share-withholding for taxes rather than open-market sales. After these transactions, Muzzey directly holds 329,275 shares of common stock.
MYRIAD GENETICS INC Chief Legal Officer Jennifer Lynne Fox reported equity compensation and related tax withholding transactions in company common stock. On March 12, 2026, she acquired 195,876 time-based restricted stock units granted under the 2017 Employee, Director and Consultant Equity Incentive Plan, with each unit representing one share of common stock that vests in three equal annual installments beginning on the first anniversary of the grant date. On March 13, 2026, 5,995 shares were withheld by the company at a price of $4.66 per share to satisfy tax obligations related to previously vesting restricted stock units. Following these transactions, she directly holds 310,362 shares of common stock.
Donnelly Brian J reported acquisition or exercise transactions in this Form 4 filing.
MYRIAD GENETICS INC Chief Commercial Officer Brian J. Donnelly reported an equity compensation grant of 226,804 shares of common stock in the form of time-based restricted stock units at a price of $0.00 per share.
Each restricted stock unit represents a contingent right to receive one share of common stock and will vest in three equal annual installments beginning on the first anniversary of the grant date. Following this award, Donnelly holds 624,338 shares of common stock directly.
Myriad Genetics’ Chief Operating Officer Mark Verratti reported routine equity compensation activity. On March 12, 2026, he acquired 247,423 time-based restricted stock units, each representing one future share that vests in three equal annual installments starting one year after the grant.
On March 13–15, 2026, a total of 29,289 shares of common stock were withheld at $4.66 per share to cover tax obligations tied to the vesting of previously granted time-based and performance-based restricted stock units. After these transactions, Verratti directly held 632,770 shares of Myriad Genetics common stock.
Myriad Genetics Chief Financial Officer Benjamin Richard Wheeler reported equity compensation and related tax withholding transactions in company common stock. On March 12, 2026, he received 206,186 time-based restricted stock units, each representing one future share, vesting in three equal annual installments beginning on the first anniversary of the grant date.
Between March 13 and March 15, 2026, a total of 4,752 shares of common stock were withheld by the company to cover tax obligations tied to vesting of previously granted time-based and performance-based restricted stock units. These are tax-withholding dispositions rather than open-market sales. After these transactions, Wheeler directly holds 299,058 shares of Myriad Genetics common stock.